20 Units of Semaglutide Is How Many mg? The Unit Math Explained (2026)
20 units of semaglutide is how many mg? There is no single answer for every vial, because a “unit” here is not a fixed amount of drug. It is a volume mark borrowed from insulin syringes, and the milligram total depends on the concentration you are measuring.
This page walks through that arithmetic: what a unit measures, how concentration turns it into milligrams, and where common concentrations come from. It does not recommend a dose; that call belongs to a licensed prescriber or pharmacist, not a syringe chart.
The Compound Universe Take: On a standard U-100 insulin syringe, 20 units always equals 0.2 mL, since that syringe is printed with 100 units per mL. The milligram amount inside that 0.2 mL depends on concentration: at 1.34 mg/mL (an Ozempic pen strength) it is about 0.27 mg, at 2.5 mg/mL (a common reconstituted-vial concentration) it is 0.5 mg, and at 5 mg/mL it is 1 mg. Confirm the actual labeled concentration before doing this math, and treat any dosing question as one for a licensed prescriber or pharmacist.
Need a concentration that is not listed below? Try Compound Universe’s unit-to-mg calculator for an instant result.
What “units” actually mean on a semaglutide syringe
Insulin syringes carry a units scale because insulin dosing has used units for a century. A standard U-100 syringe holds 100 units per milliliter, so 1 unit equals 0.01 mL and 20 units equal 0.2 mL [1].
Semaglutide has no FDA-recognized “unit” of biological potency like insulin. Measuring semaglutide with an insulin syringe reuses its printed volume scale as a ruler, not a semaglutide-specific unit. The syringe barrel encodes a volume scale, not a drug-specific potency scale, so a unit count alone never gives you the milligram amount.
| Concentration | Typical source | Volume at 20 units | mg in 20 units |
|---|---|---|---|
| 0.68 mg/mL | Ozempic 2 mg/3 mL pen | 0.2 mL | about 0.136 mg |
| 1.34 mg/mL | Ozempic 4 mg/3 mL pen | 0.2 mL | about 0.268 mg |
| 2.5 mg/mL | Common reconstituted-vial example | 0.2 mL | 0.5 mg |
| 2.68 mg/mL | Ozempic 8 mg/3 mL pen | 0.2 mL | about 0.536 mg |
| 5 mg/mL | Common reconstituted-vial example | 0.2 mL | 1.0 mg |
The units-to-mg formula, worked through
The formula has two steps. First, units divided by 100 (for a U-100 syringe) gives milliliters. Second, multiply that volume by the concentration in mg/mL: mg = (units / 100) x concentration (mg/mL). For 20 units at 2 mg/mL, that is 0.2 x 2, or 0.4 mg.
The formula also runs backward: divide the mg target by concentration to get mL, then multiply by 100 for units. A 0.5 mg target at 2.5 mg/mL is 0.2 mL, or 20 units. Every number shifts if concentration shifts, which is why this question has no single universal answer.
Why concentration is the variable that decides the answer
Concentration is set during reconstitution, when a freeze-dried (lyophilized) powder is mixed with a liquid diluent to form an injectable solution. The resulting mg/mL depends on the powder-to-diluent ratio, so two vials holding the same total milligrams can end up at very different concentrations.
That is why generic “units” figures online are unreliable without a labeled concentration: a vial at 2 mg/mL and one at 10 mg/mL share the same syringe scale, yet 20 units differs five-fold in milligrams. Start from the concentration printed on your own vial or pen, not a forum post.
U-100 vs. other syringe markings
Most syringes sold for this purpose in the United States today are U-100, matching the standard for modern human insulin [1]. Older or veterinary insulin sometimes uses U-40 or U-50 syringes with a different mL-per-unit ratio, so running U-100 math on a non-U-100 syringe gives a volume error, not a rounding error. Confirm the barrel reads “U-100” before converting.
How this compares to FDA-approved semaglutide dosing
FDA-approved semaglutide products skip the “units” system entirely. Ozempic and Wegovy are dispensed as prefilled, dial-a-dose pens delivering a fixed milligram amount per click, set by the prescribing information, not drawn up from a vial [2][3].
Semaglutide is a GLP-1 receptor agonist: it activates the same receptor the body’s own GLP-1 hormone binds, part of how it slows gastric emptying and affects insulin and glucagon release (Human, via the FDA approval program) [2][4]. Its terminal half-life runs close to a week, the reason it is dosed weekly rather than daily (Human/Regulatory, per its labeling and discovery literature) [4]. The units-and-vial pattern here shows up almost only with non-pen, vial-based semaglutide, a far more restricted lane than the approved pens.
Read this before doing any math with a real vial: This page explains unit-to-mg arithmetic and terminology for educational purposes. It is not medical or dosing advice, and it does not recommend a dose, a schedule, or a source. Compounded GLP-1 medications are tightly restricted as of July 2026 (see the status table below), and any decision about what to take, and how much, must come from a licensed prescriber or pharmacist.
As of July 2026, compounding a copy of an FDA-approved semaglutide product is no longer broadly permitted. FDA removed semaglutide from its drug shortage list on February 21, 2025, ending the emergency compounding allowance 503A pharmacies (until April 22, 2025) and 503B facilities (until May 22, 2025) had relied on [5]. Only narrow, patient-specific compounding remains allowed today, not mass “essentially a copy” production.
FDA has since proposed excluding all three, semaglutide, tirzepatide, and liraglutide, from the 503B bulk drug substances list entirely (April 30, 2026); comments closed June 29, 2026, with a decision pending [6]. It has also sent 2026 warning-letter waves to telehealth companies over misleading compounded-GLP-1 marketing: 30 companies in an earlier wave, then 25 more issued June 8 and posted June 16 [7].
None of this changes the arithmetic here, but it is why a “research use only” label is not a safety or legal green light. For the wider peptide legal picture, see Compound Universe’s peptide legal-status tracker.
| Compound | FDA-approved brand(s) | Compounding status | Key date |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Mass “copy” compounding no longer permitted; narrow patient-specific compounding only | Shortage resolved Feb 21, 2025 |
| Tirzepatide | Mounjaro, Zepbound | Same restricted status; resolved earlier | Enforcement discretion ended by mid-March 2025 |
| Liraglutide | Victoza, Saxenda | Included in the same proposed exclusion | Exclusion proposed Apr 30, 2026 |
| “Research use only” vials | None (not FDA-approved for human use) | RUO labeling does not permit human-use marketing; active enforcement | 25 letters posted Jun 16, 2026 |
Key takeaways
- 20 units on a U-100 syringe is always 0.2 mL, since that syringe is scaled at 100 units per milliliter [1].
- The milligram amount depends on concentration: 0.2 mL at 1.34 mg/mL is about 0.27 mg, while 0.2 mL at 5 mg/mL is 1 mg.
- Semaglutide has no official “unit” of potency; the units scale is borrowed from insulin syringes to measure volume.
- FDA-approved semaglutide (Ozempic, Wegovy) is dosed in mg via a pen, not drawn up in units from a vial [2][3].
- Compounded semaglutide is tightly restricted as of mid-2026, with mass “copy” compounding no longer permitted and a proposed rule that would close the 503B bulks pathway entirely [5][6].
Frequently asked questions
20 units of semaglutide is how many mg?
It depends on concentration: 20 units is always 0.2 mL on a U-100 syringe, and multiplying that by the labeled mg/mL gives the milligram figure, for example 0.5 mg at a 2.5 mg/mL concentration.
How do I convert semaglutide units to mg?
Divide the units by 100 to get milliliters, then multiply by the solution’s concentration in mg/mL: mg = (units / 100) x concentration.
What does U-100 mean on an insulin syringe?
It means the syringe is scaled so 100 units equal 1 mL, the standard for most human insulin sold in the United States today [1].
Is a “unit” the same thing as a milligram for semaglutide?
No. A unit is a volume mark on the syringe barrel; semaglutide has no standardized potency “unit” like insulin, so units convert to mg only once you know the concentration.
Why do semaglutide vial concentrations vary so much?
Concentration is set during reconstitution, when a freeze-dried powder is mixed with a diluent; different ratios give different mg/mL even from vials with the same total milligrams.
Is compounded semaglutide legal right now?
As of July 2026, mass compounding of a copy of FDA-approved semaglutide is not broadly permitted; only narrow, patient-specific compounding remains, and FDA has proposed closing the 503B pathway entirely [5][6]. Legal status can change, so confirm it with a licensed prescriber or pharmacist first.
Unit-to-mg questions like this sit where dosing arithmetic meets semaglutide’s regulatory story: the U-100 syringe scale, concentration in mg/mL, and reconstitution interact with the fact that semaglutide, unlike insulin, has no standardized potency unit, while FDA-approved Ozempic and Wegovy dose in fixed milligrams per pen click instead; Compound Universe tracks the arithmetic and the regulatory status separately so neither gets mistaken for the other.
20 units of semaglutide is how many mg, in the end, is a question about concentration, not the number 20. Multiply the volume that 20 units represents, 0.2 mL on a standard U-100 syringe, by the labeled mg/mL of the solution, and the milligram figure follows directly. What the arithmetic cannot do is replace a licensed prescriber’s judgment about whether, and how much, semaglutide should be used.
Compare next: semaglutide vs. tirzepatide unit math
References
- MedlinePlus Medical Encyclopedia (NIH/NLM). Giving an insulin injection (U-100 standard: 100 units per mL).
- FDA. OZEMPIC (semaglutide) injection prescribing information, NDA 209637 (accessdata.fda.gov).
- FDA. WEGOVY (semaglutide) injection prescribing information, NDA 215256 (accessdata.fda.gov).
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID 31031702.
- FDA. Semaglutide removed from drug shortage list, Feb 21, 2025; 503A discretion ended Apr 22, 2025; 503B ended May 22, 2025.
- FDA. Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, Apr 30, 2026; Federal Register, May 1, 2026, Docket 2026-08552; comments closed Jun 29, 2026.
- FDA. Warning letters to telehealth companies on compounded GLP-1 marketing claims; 30 issued in an earlier 2026 wave, plus 25 more issued Jun 8, 2026 and posted Jun 16, 2026.